LIVE WEBINAR
Tuesday, October 13 | 2pm ET
Duration: 1 hour
Can't make the live date? Register and we'll send you a link to the recording. ​

AI promises to transform drug discovery, cutting failure rates by 20% and saving as much as $1 billion for each new therapy that reaches patients.  But with most AI projects still in the pilot phase, the gap between what AI might do and the measurable value it currently produces seems especially wide. 

How can biopharmaceutical leaders identify investments in AI that will pay off and ones that won’t? In this webinar, leaders from companies across the AI value chain lead a candid conversation about what’s working in AI-driven drug discovery, what isn’t, and why. They’ll share lessons learned from real-world experiences, offer actionable advice about how to prepare for the industry’s future, and explain:

• Where AI is delivering measurable ROI in drug discovery today, and where its promise remains unrealized
• Best practices for scaling AI projects from pilot to production 
• How to maximize the value of generative models, AI agents and agent skills  

SPEAKERS

Ilya Burkov
Global Head of Healthcare & Life Sciences, Nebius

Roy Tal Dew
Global DevRel for Biology, NVIDIA

Dov Gertz
CEO, Converge Bio